<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aardvark Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Aardvark Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aardvark-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835406d0eaa31f6af967689.webp</url>
<title>Aardvark Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-voluntary-pause-of-phase-3-hero-trial-in-prader-willi-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-voluntary-pause-of-phase-3-hero-trial-in-prader-willi-syndrome</guid>
<pubDate>Fri, 27 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and sa</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-130000198</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-130000198</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that (i) on February 9, 2026, five new employees were granted inducement awards consisting of stock options to purchase an aggregate of 147,213 shares of common stock and (ii) on February 11, 2026, one n</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Leadership Appointments</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-leadership-appointments-130000594</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-leadership-appointments-130000594</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun’s role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. T</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-establishment-u-130000954</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-establishment-u-130000954</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that it has established Ardia Therapeutics, Inc. (Ardia), a new wholly-owned U.S. subsidiary. Ardia will support development of a new dermatology pipeline focused on lead asset, DIA-615, a potential topi</description>
</item>
<item>
<title>Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-fda-submission-130000478</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-fda-submission-130000478</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United StatesSAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States fo</description>
</item>
<item>
<title>Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-first-patient-210500828</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-first-patient-210500828</guid>
<pubDate>Wed, 10 Dec 2025 21:05:00 GMT</pubDate>
<description>Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel,</description>
</item>
<item>
<title>Aardvark Therapeutics to Present at Upcoming Investor Conferences in December</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-210500327</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-210500327</guid>
<pubDate>Tue, 25 Nov 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December: Piper Sandler 37th Annual Healthcare Conference in New YorkPresentation: Wednesday, December 3 at 8:00 a.m. ETEvercore ISI 8th Annual Healthca</description>
</item>
<item>
<title>Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-third-quarter-210500124</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-third-quarter-210500124</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced glucose control, along with preservation of lean body mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape Oral</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grant-210500191</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grant-210500191</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 4,881 shares of common stock. The option was granted pursuant to the Aardvark Therapeu</description>
</item>
<item>
<title>Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-presents-data-supporting-170000391</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-presents-data-supporting-170000391</guid>
<pubDate>Tue, 04 Nov 2025 17:00:00 GMT</pubDate>
<description>New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape Preclinical and clinical data demonstrates the potential of ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after the discontinuation of GLP-1RA Aardvark to host investor webinar on November 5th, 2025 to review ARD-101 and ARD-201 programs, as</description>
</item>
<item>
<title>Aardvark Therapeutics to Present at Upcoming Investor Conferences in November</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-130000316</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-130000316</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during November: Stifel 2025 Healthcare Conference in New YorkPresentation: Tuesday, November 11 at 4:40 p.m. ET TD Cowen Treatment Advancements in Obesity & R</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-data-pipeline-120000736</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-data-pipeline-120000736</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present poster presentations at ObesityWeek 2025, which</description>
</item>
<item>
<title>Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-fda-alignment-120000431</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-fda-alignment-120000431</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient PopulationSAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announces alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment to the company’s Phase 3 HERO trial of</description>
</item>
<item>
<title>Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-stifel-2025-200500110</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-stifel-2025-200500110</guid>
<pubDate>Tue, 23 Sep 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 at 9:00 a.m. Eastern time. A live webcast presentation will be accessible on the company’s website, www.aardvarkther</description>
</item>
<item>
<title>Aardvark Therapeutics to Present at Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-201000092</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-present-upcoming-investor-201000092</guid>
<pubDate>Wed, 27 Aug 2025 20:10:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September: Cantor Fitzgerald Global Healthcare Conference 2025 in New YorkPresentation: Wednesday, September 3 at 11:30 a.m. ET Morgan Stanley 23rd Annu</description>
</item>
<item>
<title>Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-second-quarter-201000825</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-reports-second-quarter-201000825</guid>
<pubDate>Wed, 13 Aug 2025 20:10:00 GMT</pubDate>
<description>Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to focus on durable weight loss as a monotherapy and in combination with GLP-1RA.Anticipated expansion of Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) to include pediatric population you</description>
</item>
<item>
<title>Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-ard-201-120000457</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-ard-201-120000457</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain after discontinuation of tirzepatide.In combination with low-dose tirzepatide, ARD-201 improved weight loss compared to high dose tirzepatide alone.Aardvark plans two separate Phase 2 clinical trials for ARD-201: Phase 2 POWER trial to focus on weight rebound in patients discontinuing GLP-1RA therapy,</description>
</item>
<item>
<title>Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)</title>
<link>https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/aardvark-therapeutics-inc-common-stock/news/aardvark-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Fri, 18 Jul 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on</description>
</item>
</channel>
</rss>